NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
Innovent Biologics (Suzhou) Co. Ltd.
Fudan University
Sun Yat-sen University
Sun Yat-sen University